A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

NCT00287079 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Clinically Isolated Syndrome

Interventions

DRUG: Rebif®
OTHER: No Treatment

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]